US Patent Issued to Venn Biosciences on April 29 for "Biomarkers for diagnosing non-alcoholic steatohepatitis (NASH) or hepatocellular carcinoma (HCC)" (California Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,287,342, issued on April 29, was assigned to Venn Biosciences Corp. (South San Francisco, Calif.).

"Biomarkers for diagnosing non-alcoholic steatohepatitis (NASH) or hepatocellular carcinoma (HCC)" was invented by Prasanna Ramachandran (Menlo Park, Calif.) and Gege Xu (Redwood City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Embodiments described herein generally relate to technologies for analyzing peptide structures for diagnosing and/or treating a disease state advancing through a disease progression. A non-limiting example of a method relating to the technologies described in the subject application may include receiving peptide structure ...